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IDENTIFICATION OF AN AUC OF 7603 UMOL*MIN/HR PER DAY X 4 DAYS
AS THE MAXIMUM TOLERATED DOSE (MTD) OF IV CONTINUOUS INFU-
SION (CI) BUSULFAN (BU) WITH FIXED DOSE FLUDARABINE (FLU) IN
A PHARMACOKINETICALLY-BASED DOSE PHASE I STUDY IN PATIENTS
(PTS) WITH HEMATOLOGIC MALIGNANCIES UNDERGOING ALLOGENEIC
STEM CELL TRANSPLANTATION
Wood, W.A., Walko, C.M., Rao, K.V., Whitley, J., Moore, D.T.,
Gabriel, D.A., Serody, J.S., Coghill, J.M., Shea, T.C. University of North
Carolina at Chapel Hill, Chapel Hill, NC
We previously demonstrated the benefit of using a test-dose of IV
Busulfan to predict systemic exposure in patients with hematologic
malignancies undergoing allogeneic stem cell transplant (Walko et
al, J Clin Oncol, ASCO, 24, : 16502, 2006). We now report on
this approach in 30 pts receiving a 90-hrCI of Bu in a dose-escalation
study.
Methods: Pts received a 0.8 mg/kg test dose over 2 hours and PK
sampling at 0, 2.5, 4, 5, and 6 hours one week prior to initiation of
full-dose treatment. Conditioning consisted of 30 mg/m2 Flu qd 
5 and targeted Bu to achieve an AUC of 4800 (9 pts), 5760 (6 pts),
6912 (8 pts), 7603 (3 pts) or 8363 (2 pts) umol*min/hr/d on days
-7 to -3. PK sampling occurred at hours 0, 12, 16, 18, 48, 60, 72,
and 89.5. All pts received tacrolimus and IV alemtuzumab in doses
of 30mg for matched related donors (MRD) or 60mg for matched
unrelated donors (MUD) for prevention of GVHD.
Results: 30 pts (14 MRD, 16 MUD) ages 18–55 (median 37) with
high-risk AML (11), ALL (7), MDS (4), or other (8) were enrolled.
All engrafted with a median of 13 days to ANC i 500 and 14 days
to platelet count i 20Kwith no late graft failures. There were 9 treat-
ment related deaths. Seven were from infection: pneumonia (1) and
biliary sepsis (1) prior to day 100, and aspergillus (2), nocardia (1),
biliary sepsis (1), and hemorrhagic cystitis (1) after day 100. One
death was from late VOD and liver failure (d 201), and one from
leukoencephalopathy (d 196). Grade 4 toxicities included 3 cases of
mucositis (2 at dose level 5, AUC 8363, and 1 at level 2), and 1 liver
failure at level 2. Grade 3 toxicities included mucositis (8), hepatitis
(3) pneumonia (2) and seizures (1). 11 pts developed grade 2, two
grade 3, and one grade 4 aGVHD. Two pts developed extensive
and two developed limited cGVHD. 11 pts (37%) relapsed at a
median of 117 days (range 17–652) post-transplant. PFS at 18
months was 36%. The MTD was level 4 with a target AUC of
7603 umol*min/hr per day 4 days. Dose limiting toxicity was grade
4 mucositis in 2/2 pts at dose level 5 with an actual mean AUC of
8600 umol*min/hr per day  4 days.
Conclusion: This approach permits accurate delivery of a 55%
increase in target systemic exposure to IV Bu compared to the stan-
dard AUC of 4800 umol*min/hr per day x 4 days, is well-tolerated,
and will be studied in a Phase II trial with ATG and MTX as
GVH prophylaxis in an attempt to reduce the rate of deaths from
late infections and relapse.271
A STRATEGY FOR DISTINGUISHING SNP IDENTITY IN MULTIPLE-
DONORS INVOLVED IN HAPLOIDENTICAL BONE MARROW TRANSPLAN-
TATION
Chen, X., Hofmann, T.J., Otsuru, S., Jethva, R., Horwitz, E.M. The
Children’s Hospital of Philadelphia, Philadelphia, PA
Chimerism is an important index in hematopoietic cell transplan-
tation (HCT). Determination of chimerism can be challenging in
cases of multiple-donors, such as second allogeneic HCT, double-
cord blood transplantation, or novel cell therapies. Commonly
used methods used to estimate chimerism include cytogenetic anal-
ysis in sex disparate transplantations and molecular analysis of poly-
morphic tandem repeat sequences; however, these techniques areeither restricted by gender or inefficient sensitivity. Single nucleotide
polymorphisms (SNPs) are the most common source of human
genetic diveristy, providing a virtually unlimited resource of molec-
ular markers that can be used to distinguish individuals. In principle,
real-time PCR-based assays can be used to assess SNPs, and such
assays demonstrate a substantially higher sensitivity (0.001%), but
the specificity is unclear due to a low level signal from mismatched
sequences. In this study, we cloned 14 pairs of SNPs selected from
the SNP HapMap database and examined the specificity and sensi-
tivity of their detection by real-time PCR. We also explored the
efficacy of using SNP assays to measure chimerism. Each PCR reac-
tion includes two primer/fluorescent probe pairs to allow genotyping
of the two possible variants at the SNP site in a target template
sequence. We found that both the polymorphic nucleotide as well
as the sequence immediately adjacent to the polymophism influences
the ability to distinguish a signal between the target and mismatched
sequences. Moreover, the specific fluorescent reporter probe can
affect the difference in signal intensity between the target and mis-
matched sequences which determines the specificity of the assay.
By optimal selection of the polymorphic sequences and fluorescent
reporter, the real-time PCR SNP assay of chimerism can attain a
sensitivity of 0.1%–0.5%with nearly 100% specificity. This strategy
will be applied in upcoming clinical trials of bone marrow cell
therapy.
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IMPACT OF CYTOGENETICS AND MARROW REMISSION STATUS ON
DISEASE PROGRESSION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
(AML) OR MYELODYSPLASTIC SYNDROME (MDS) UNDERGOING ALLO-
GENEIC STEM CELL TRANSPLANTATION
Koca, E., Saliba, R.M., de Lima, M., Popat, U., Kebriaei, P., Rondon, G.,
Zhang,W., Giralt, S., Andersson, B.A., Champlin, R. University of Texas
MD Anderson Cancer Center, Houston, TX
Our aim was to determine the impact of cytogenetics and remis-
sion status on outcome of AML orMDS pts treated with allogeneic
stem cell transplantation (alloSCT) conditioned with busulfan
(Bu) based regimens. We reviewed retrospectively all pts who re-
ceived alloSCT at MD Anderson Cancer Center for AML or
MDS between 1990 and 2007 conditioned with Bu (1 mg/kg IV
q 6h 4 days) and cyclophosphamide (60 mg/kg IV  2 days),
Bu and fludarabine (Flu) in myeloablative (Bu 130 mg/m2 4
days and Flu 40 mg/m2 4 days) or reduced intensity doses. Pts
in first or subsequent remission and those achieving morphologic
remission after initial induction treatment but without platelet re-
covery to .100,000/mcl (marrow remission) were included in the
analysis. Pts were categorized according to the Dana-Farber cyto-
genetics classification. Cox’s regression analysis was used to evalu-
ate prognostic factors for disease progression, overall survival (OS)
and progression free survival (PFS). Among 265 pts (median age 45
[5–69]) diagnoses were AML (n 5 217), MDS (n 5 17) and AML
evolving from MDS (n 5 31). Disease status at alloSCT was; first
complete remission (CR) (n 5 129), advanced remission (beyond
first CR) (n 5 93) and marrow remission (n 5 43). Majority of
the donors were matched related (n 5 152) or matched unrelated
(n 5 94). Stem cell source was bone marrow (n 5 108), peripheral
blood (n 5 153) or cord blood (n 5 4). Median follow-up time of
surviving pts was 39 months (1.6–189). The 3 years actuarial prob-
ability of OS was 55% and PFS 49%. On univariate analysis, ad-
verse cytogenetics were associated with higher disease
progression rate (p\0.05). There was also a trend for worse OS
(p 5 0.09) and PFS (p 5 0.098) for adverse cytogenetics. In addi-
tion pts in ‘‘marrow remission’’ compared to those who were in CR
with full platelet recovery prior to transplant had a significantly
higher rate of disease progression (p 5 0.001) and poorer 3 years
OS (37% vs 59%, p 5 0.001) and PFS (30% vs 53%, p 5 0.001).
Outcomes were comparable for pts in first and advanced remis-
sions. Pts with de novo AML had more favorable OS (p 5 0.02)99
